Back

Exelixis Inc

Ticker: EXEL ISIN: US30161Q1040
Add to portfolio Portfolio analysis in 2min
Stock Mid-cap Trading above 200-day average Near 52-week high
Market cap
$9.25B
P/E
20.89
Forward P/E
18.83
Profit margin
22.43%
Revenue growth QoQ
14.30%
Beta
0.51
$54.45 -1.47%
Price as of 2026-08-28 · NASDAQ

Performance by timeframe

Rolling returns
1 Month -1.11%
6 Months +32.71%
1 Year +46.45%
5 Years +22.77% p.a.+178.66%
10 Years +16.80% p.a.+371.84%
Since inception +5.03% p.a.+240.31%
Calendar year returns
YTD +24.23%
2025 +31.62%
2024 +38.81%
2023 +49.56%
2022 -12.25%
2021 -8.92%

Key stats

Market cap
9.25B
P/E
20.89
Beta
0.51
52-week range
20.02 - 37.59
50-day MA
34.93
200-day MA
27.23
Section 1

Business overview

Company profile data from fundamentals.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Sector Healthcare
Industry Biotechnology
Country United States
Exchange NASDAQ
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 20.20%
ROA 12.81%
Profit margin 22.43%
Operating margin 34.81%
PEG ratio 2.27
Revenue/share TTM 7.03
Revenue TTM 2.08B
EBITDA 635.96M
Gross profit TTM 2.00B
Beta 0.51

Valuation

Trailing P/E 20.89
Forward P/E 18.83
P/B 4.06
P/S 4.44
EV/EBITDA 12.98
EV/Revenue 3.96
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 1.96
Quarterly earnings growth 121.70%
Revenue TTM 2.08B
Reported quarters 101
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $34.47
Analyst rating 3.9546

Ownership & short interest

Shares outstanding 285.58M
Shares float 238.46M
Institutional ownership 89.15%
Insider ownership 1.78%
Short ratio 5.24
Short % of float 4.92%

Details

Instrument metadata and source update timestamps.

Symbol EXEL
Name Exelixis Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US30161Q1040
Country USA
Code + exchange EXEL.NASDAQ
Fundamentals updated 2025-01-26

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.